José Alfonso Alvarez-Castro

Dr. José Alfonso Alvarez-Castro

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in World Neurosurgery
Verified
Journal Article
Closed access
PPPavel S. Pichardo-Rojas
Pavel S. Pichardo-Rojas
JAJuan Carlos Angulo-Lozano
Juan Carlos Angulo-Lozano
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
DVDiego Vázquez-Alva
Diego Vázquez-Alva
RORicardo Alfonso Osuna-Lau
Ricardo Alfonso Osuna-Lau
YEYoshua Esquenazi
Yoshua Esquenazi

20 June 2024 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
AHAlan Hernández-Hernández
Alan Hernández-Hernández
RURodrigo Uribe-Pacheco
Rodrigo Uribe-Pacheco
GGGerardo Yoshiaki Guinto-Nishimura
Gerardo Yoshiaki Guinto-Nishimura
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
FCFernando Castro-Soto
Fernando Castro-Soto
NANicasio Arriada-Mendicoa
Nicasio Arriada-Mendicoa

10 November 2022 in Cureus
Verified
Journal Article
Open access
KAKeren Magaly Aguilar-Hidalgo
Keren Magaly Aguilar-Hidalgo
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
JSJosé Omar Santellán-Hernández
José Omar Santellán-Hernández
ACAna Laura Calderón-Garcidueñas
Ana Laura Calderón-Garcidueñas
GRGerardo Romero-Luna
Gerardo Romero-Luna
SPSonia iliana Mejia Perez
Sonia iliana Mejia Perez
Gangliogliomas are central nervous system (CNS) tumors with a neuronal and glial component considered grade 1 according to the World Health Organization (WHO) classification. On the other hand, oligodendrogliomas are diffuse infiltrating gliomas (CNS WHO grade 2 or 3) characterized by both an isocitrate dehydrogenase mutation and 1p/19q co-deletion. There have been some cases with the coexistence of these two tumors. Here, we present the case of a low-growing left frontoparietal brain tumor with a definite diagnosis of ganglioglioma (CNS WHO grade 1) and oligodendroglioma (CNS WHO grade 2) with areas of anaplastic oligodendroglioma (CNS WHO grade 3) in a patient with long-standing epilepsy.

24 March 2023 in Surgical Neurology International
Verified
Journal Article
Open access
JSJose Omar Santellan-Hernandez
Jose Omar Santellan-Hernandez
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
KAKeren Magaly Aguilar-Hidalgo
Keren Magaly Aguilar-Hidalgo
FSFernando Castro Soto
Fernando Castro Soto
JEJonathan Ramos Escalante
Jonathan Ramos Escalante
SPSonia iliana Mejia Perez
Sonia iliana Mejia Perez
Background: Glioblastoma multiforme represents approximately 60% of all brain tumors in adults. This malignancy shows a high level of biological and genetic heterogeneity associated with exceptional aggressiveness, leading to poor patient survival. One of the less common presentations is the appearance of primary multifocal lesions, which are linked with a worse prognosis. Among the multiple triggering factors in glioma progression, the administration of sex steroids and their analogs has been studied, but their role remains unclear to date. Case Description: A 43-year-old transgender woman who has a personal pathological history of receiving intramuscular (IM) hormone treatment for 27 years based on algestone/estradiol 150 mg/10 mg/mL. Three months ago, the patient suddenly experienced hemiplegia and hemiparesis in her right lower extremity, followed by a myoclonic focal epileptic seizure, vertigo, and a right frontal headache with a visual analog scale of 10/10. Magnetic resonance imaging images revealed an intra-axial mass with poorly defined, heterogeneous borders, and thick borders with perilesional edema in the left parietal lobe, as well as a rounded hypodense image with well-defined walls in the right internal capsule. The tumor was resected, and samples were sent to the pathology department, which confirmed the diagnosis of wild-type glioblastoma. Conclusion: This report identifies prolonged use of steroid-based hormone replacement therapy as the only predisposing factor in the oncogenesis of multifocal glioblastoma. It is an example that highlights the importance for physicians not to consider pathologies related to the human immunodeficiency virus rather than neoplasms in transgender patients in view of progressive neurological deterioration.

8 September 2023 in Surgical Neurology International
Verified
Journal Article
Open access
JRJonathan Ramos-Escalante
Jonathan Ramos-Escalante
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
MSMarcos V. Sangrador-Deitos
Marcos V. Sangrador-Deitos
GGGerardo Yoshiaki Guinto-Nishimura
Gerardo Yoshiaki Guinto-Nishimura
RMRicardo Marian-Magaña
Ricardo Marian-Magaña
JGJuan Luis Gómez-Amador
Juan Luis Gómez-Amador
Background: Sinonasal neuroendocrine carcinoma is a rare head and neck tumor that represents only 5% of sinonasal neoplasms. This lesion has a high risk of invasion to adjacent structures such as the orbit, skull base, and soft tissues, with symptoms usually being nonspecific. Most cases are diagnosed in late stages, decreasing overall survival without treatment. To date, there is no consensus on management given its low prevalence; however, it has been shown that multimodal therapy, with the correct surgical approach as the mainstay, offers a better disease-free prognosis. Case Description: A 46-year-old woman presented with a 1 year history of nasal symptoms, characterized by obstruction and epistaxis. Imaging studies showed an extra-axial mass causing skull base erosion and displacement of the right fronto-orbital region, without invasion of brain parenchyma or meninges. A biopsy was performed and an unresectable poorly differentiated sinonasal neuroendocrine carcinoma was diagnosed. Treatment with radio and chemotherapy was initiated and, as the tumoral volume decreased, she was referred for neurosurgical intervention; an endonasal endoscopic approach was performed. Gross total resection was achieved and the patient was discharged without postoperative complications and no residual lesion on imaging. Conclusion: We describe the evolution of a rare advanced-stage neoplasm. It highlights that despite receiving an initial diagnosis of an unresectable mass, multimodal therapy, and an adequate surgical approach deemed the entire lesion to be resected. Despite the favorable clinical evolution, the follow-up of neuroendocrine carcinoma is prioritized as a neoplasm with a high rate of recurrence and metastasis.

30 May 2023 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
IHItzel Ariadna Hernández-Dehesa
Itzel Ariadna Hernández-Dehesa
JAJosé Alfonso Alvarez-Castro
José Alfonso Alvarez-Castro
KAKeren Magaly Aguilar-Hidalgo
Keren Magaly Aguilar-Hidalgo
JSJosé Omar Santellán-Hernández
José Omar Santellán-Hernández
FCFernando Castro-Soto
Fernando Castro-Soto